# Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

> **NCT00280917** · PHASE2 · COMPLETED · sponsor: **Can-Fite BioPharma** · enrollment: 254 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** CF101

## Key facts

- **NCT ID:** NCT00280917
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00280917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00280917, "Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00280917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*